Molecular mechanisms involved in cisplatin cytotoxicity

Cellular and Molecular Life Sciences

Volumn 57, Issue 8-9, 2000, Pages 1229-1235

  Jordan, P ^a   Carmo Fonseca, M ^b  

^a NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Anticancer drugs; Apoptosis; Cisplatin; DNA adducts; DNA repair; Nucleolus

Indexed keywords

CISPLATIN;

APOPTOSIS; CYTOTOXICITY; DNA ADDUCT; DNA DEGRADATION; DNA REPAIR; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; HUMAN; NONHUMAN; REVIEW;

EID: 0033841622     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000762     Document Type: Review

References (84)

1. 1 Rosenberg B., van Camp L. and Krigas T. (1965) Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205: 698-699
2. 2 Sherman S. E. and Lippard S. J. (1987) Structural aspects of platinum anticancer drug interactions with DNA. Chem. Rev. 86: 1153-1181
3. 3 Muggia F. M. (1991) Cisplatin update. Semin. Oncol. 18: 1-4
4. 4 Leng M., and Barbee V. (1994) DNA adducts of cisplatin, transplatin and platinum-intercalating drugs. In: DNA Adducts: Identification and Biological Significance, pp. 339-348. Hemminki K. et al. (eds), IARC Scientific Publications no. 125, International Agency for Research on Cancer, Lyons, France
5. 5 Loehrer P. J. and Einhorn L. H. (1984) Cisplatin. Annals Int. Mcd. 100: 704-713
6. 6 Pinedo H. M. and Schornagel J. H. (1996) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Plenum, New York
7. 7 Yang D. Z. and Wang A. H. J. (1997) Structural studies of interactions between anticancer platinum drugs and DNA. Prog. Biophys. Mol. Biol. 66: 81-111
8. 8 Chu G. (1994) Cellular responses to cisplatin. J. Biol. Chem. 269: 787-790
9. 9 Gelasco A. and Lippard S. J. (1998) NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin. Biochemistry 37: 9230-9239
10. 10 Takahara P. M., Rosenzweig A. C., Frederick C. A. and Lippard S. J. (1995) Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 377: 649-652
11. 11 Lindahl T., Karran P. and Wood R. D. (1997) DNA excision repair pathways. Curr. Opin. Genet. Dev. 7: 158-169
12. 12 Zample D. B. and Lippard S. J. (1995) Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem. Sci. 20: 435-439
13. 13 Zamble D. B., Mu D., Reardon J. T., Sancar A. and Lippard S. J. (1996) Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 35: 10004-10013
14. 14 Moggs J. G., Szymkowski D. E., Yamada M., Karran P. and Wood R. D. (1997) Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts. Nucleic Acids Res. 25: 480-491
15. 15 Ciccarelli R. B., Solomon M. J., Varshavsky A. and Lippard S. J. (1985) In vivo effects of cis-and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking and inhibition of replication. Biochemistry 24: 7533-7540
16. 16 Plooy A. C., Fichtinger-Schepman A. M., Schutte H. H., van Dijk M. and Lohman P. H. (1985) The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques. Carcinogenesis 6: 561-566
17. 17 Dijt F. J., Fichtinger-Schepman A. M., Berends F. and Reedijk J. (1988) Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res. 48: 6058-6062
18. 18 Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J. J. and Reed E. (1994) Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest. 94: 703-708
19. 19 States J. C. and Reed E. (1996) Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer is not associated with XPA mutations or gene amplification. Cancer Lett. 108: 233-237
20. 20 Li Q., Ding L., Yu J. J., Mu C., Tsang B., Bostick-Bruton F. et al. (1998) Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells. Int. J. Oncol. 13: 987-992
21. 21 Koberle B., Masters J. R. W., Hartley J. A. and Wood R. D. (1999) Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr. Biol. 9: 273-276
22. 22 Zlatanova J., Yaneva J. and Leuba S. H. (1998) Proteins that specifically recognize cisplatin-damaged DNA: a clue to anti-cancer activity of cisplatin. FASEB J. 12: 791-799
23. 23 Bianchi M. E. and Beltrame M. (1998) Flexing DNA: HMG-box proteins and their partners. Am. J. Hum. Genet. 63: 1573-1577
24. 24 Huang J. C., Zamble D. B., Reardon J. T., Lippard S. J. and Sancar A. (1994) HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl. Acad. Sci. USA 91: 10394-10398
25. 25 Fleck O., Kunz C., Rudolph C. and Kohli J. (1998) The high mobility group domain protein Cmbl of Schizosaccharomyces pombe binds cytosines in base mismatches and opposite chemically altered guanines. J. Biol. Chem. 273: 30398-30405
26. 26 Brown S. J., Kellett P. J. and Lippard S. J. (1993) Ixrl, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science 261: 603-605
27. 27 Jones S. L., Hickson I. D., Harris A. L. and Harnett P. R. (1994) Repair of cisplatin-DNA adducts by protein extracts from human ovarian carcinoma. Int. J. Cancer 59: 388-393
28. 28 Corda Y., Job C, Anin M.-F., Leng M. and Job D. (1991) Transcription by eucaryotic and procaryotic RNA polymerases of DNA modified at a d(GG) or a d(AG) site by the antitumor drug cis-diammindichloroplatinum(II). Biochemistry 30: 222-230
29. 29 Lemaire M. A., Schwartz A., Rahmouni A. R. and Leng M. (1991) Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum (II) and DNA. Proc. Natl. Acad. Sci. USA 88: 1982-1985
30. 30 Mello J. A., Lippard S. J. and Essigmann J. M. (1995) DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo. Biochemistry 34: 14783-14791
31. 31 Mymryk J. S., Zaniewski E. and Archer T. K. (1995) Cisplatin inhibits chromatin remodeling, transcription factor binding and transcription from the mouse mammary tumor virus promoter in vivo. Proc. Natl. Acad. Sci. USA 92: 2076-2080
32. 32 Brandt T. Y. and Ali-Osman F. (1997) Detection of DNA damage in transcriptionally active genes by RT-PCR and assessment of repair of cisplatin-induced damage in the glutathione S-transferase-pi gene in human glioblastoma cells. Toxicol. Appl. Pharmacol. 143: 22-29
33. 33 Friedberg E. C. (1996) Relationships between DNA repair and transcription. Annu. Rev. Biochem. 65: 15-42
34. 34 van Gool A. J., Van der Horst G. T. J., Citterio E. and Hoeijmakers J. H. J. (1997) Cockayne syndrome: defective repair of transcription. EMBO J. 16: 4155-4162
35. 35 Vichi P., Coin F., Renaud J.-P., Vermeulen W., Hoeijmakers J. H. J., Moras D. et al. (1997) Cisplatin-and UV-damaged DNA lure the basal transcription factor TFHD TBP. EMBO J. 16: 7444-7456
36. 36 Coin F., Frit P., Viollet B., Salles B. and Egly J. M. (1998) TATA binding protein discriminates between different lesions on DNA, resulting in a transcription decrease. Mol. Cell. Biol. 18: 3907-3914
37. 37 Vassylyev D. G., Kashiwagi T., Mikami Y., Ariyoshi M., Iwai S., Ohtsuka F. et al. (1995) Atomic model of a pyrimidine dimer excision repair enzyme complexed with a DNA substrate: structural basis for damaged DNA recognition. Cell 83: 773-782
38. 38 Treiber D. K., Zhai X., Jantzen H.-M. and Essigmann J. M. (1994) Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc. Natl. Acad. Sci. USA 91: 5672-5676
39. 39 Werner M. H., Huth J. R., Gronenborn A. M. and Cloe G. M. (1995) Molecular basis of human 46X,Y sex reversal revealed from the three-dimensional solution structure of the human SRY-DNA complex. Cell 81: 705-714
40. 40 Love J. J., Li X., Case D. A., Giese K., Grosschedl R. and Wright P. E. (1995) Structural basis for DNA bending by the architectural transcription factor LEF-1. Nature 376: 791-795
41. 41 McA'Nulty M. M., Whitehead J. P. and Lippard S. J. (1996) Binding of Ixrl, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo. Biochemistry 35: 6089-6099
42. 42 Trimmer E. E., Zamble D. B., Lippard S. J. and Fssigmann J. M. (1998) Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities. Biochemistry 37: 352-362
43. 43 Jordan P. and Carmo-Fonseca M. (1998) Cisplatin inhibits synthesis of ribosomal RNA in vivo. Nucleic Acids Res. 26: 2831-2836
44. 44 Zhai X., Beckmann H, Jantzen H. M. and Essigmann J. M. (1998) Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. Biochemistry 37: 16307-16315
45. 45 Vos J.-M. H. and Wauthier E. (1991) Differential introduction of DNA damage and repair in mammalian genes transcribed by RNA polymerases I and II. Mol. Cell. Biol. 11: 2245-2252
46. 46 Christians F. C. and Hanawalt P. C. (1993) Lack of transcription-coupled repair in mammalian ribosomal RNA genes. Biochemistry 32: 10512-10518
47. 47 Fritz L. K. and Smerdon M. J. (1995) Repair of UV damage in actively transcribed ribosomal genes. Biochemistry 34: 13117-13124
48. 48 Moss T. and Stefanovsky V. Y. (1995) Promotion and regulation of ribosomal transcription in eukaryotes by RNA polymcrasc I. Prog. Nucleic Acid Res. Mol. Biol. 50: 25-66
49. 49 Cece R., Petrucciolo M. G., Cavaletti G., Barajon I. and Tredici G. (1995) An ultrastructural study of neuronal changes in dorsal root ganglia of rats after chronic cisplatin administration. Histol. Histopathol. 10: 837-845
50. 50 Pinto A. L. and Lippard S. J. (1985) Sequence-dependent termination of in vitro DNA synthesis by cis-and trans-diamminedichloroplatinum (II). Proc. Natl. Acad. Sci. USA 82: 4616-4619
51. 51 Sorenson C. M. and Eastman A. (1988) Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res. 48: 6703-6707
52. 52 Allday M. J., Inman G. J., Crawford D. H. and Farrell P. J. (1995) DNA damage in human B cells can induce apoptosis, proceeding from G1 S when p53 is transactivation competent and G2 M when it is transactivation defective. EMBO J. 14: 4994-5005
53. 53 Gong J, Costanzo A., Yang H.-Q., Melino G., Kaelin W. G. Jr, Levrero M. et al. (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399: 806-809
54. 54 Anthoney D. A., McIlwrath A. J., Gallagher W. M., Edlin A. R. M. and Brown R. (1996) Microsatellite instability, apoptosis and loss of p53 function in drug-resistant tumour cells. Cancer Res. 56: 1374-1381
55. 55 Gallagher W. M., Cairney M., Schott B., Roninson I. B. and Brown R. (1997) Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene 14: 185-193
56. 56 Zamble D. B., Jacks T. and Lippard S. J. (1998) p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc. Natl. Acad. Sci. USA 95: 6163-6168
57. 57 Jost C. A., Mrin M. C. and Kaelin W.G. Jr (1999) p73 is a human p53-reiated protein that can induce apoptosis. Nature 389: 191-194
58. 58 Kharbanda S., Ren R., Pandey P., Shafman T. D., Feller S. M., Weichelbaum R. et al. (1995) Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 376: 785-788
59. 59 Liu Z. G., Baskaran R., Lea-Chou E. T., Wood L. D., Chen Y., Karin M. et al. (1996) Three distinct signalling responses by murine fibroblasts 10 genotoxic stress. Nature 384: 273-276
60. 60 Agami R., Blandino G., Oren M. and Shaul Y. (1999) Interaction of c-Abl and p73α and their collaboration to induce apoptosis. Nature 399: 809-813
61. 61 Yuan Z., Shioya H., Ishiko T., Sun X., Gu J., Huang Y. Y. et al. (1999) p73 is regulated by tyrosine-kinase c-Abl in the apoptotic response to DNA damage. Nature 399: 814-817
62. 62 Strasser A., Harris A. W., Jacks T. and Cory S. (1994) DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bel-2. Cell 79: 329-339
63. 63 Zanke B. W., Boudreau K., Rubie E., Winnettt E., Tibbles L. A., Zon L. et al. (1996) The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat. Curr. Biol. 6: 606-613
64. 64 Sanchez-Perez I., Murguia J. R. and Perona R. (1998) Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogcne 16: 533-540
65. 65 Ishibashi T. and Lippard S. J. (1998) Telomere loss in cells treated with cisplatin. Proc. Natl. Acad. Sci. USA 95: 4219-4223
66. 66 Strathdee G., MacKean M. J., Illand M. and Brown R. (1999) A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18: 2335-2341
67. 67 Mello J. A., Acharya S., Fishel R. and Essigmann J. M. (1996) The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem. Biol. 3: 579-589
68. 68 Duckett D. R., Drummond J. T., Murchie A. I., Reardon J. T., Sancar A., Lilley D. M. et al. (1996) Human MutSα recognizes damaged DNA base pairs containing O6-methyguanine, O4-methylthymine or the cisplatin-d(GpG) adduct. Proc. Natl. Acad. Sci. USA 93: 6443-6447
69. 69 Yamada M., O'Regan E., Brown R. and Karran P. (1997) Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic Acids Res 25: 491-496
70. 70 Drummond J. T., Anthoney A., Brown R. and Modrich P. (1996) Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumour cell line. J. Biol. Chem. 271: 19645-19648
71. 71 Aebi S., Kurdi-Haidar B., Gordon R., Cenni B., Zheng H., Fink D. et al. (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56: 3087-3090
72. 72 Vaisman A., Varchenko M., Umar A., Kunkel T. A., Risinger J. I., Barrett J. C. et al. (1998) The role of hMLH1, hMSH3 and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicatie bypass of platinum-DNA adducts. Cancer Res. 58: 3579-3585
73. 73 Fink D., Nebel S., Norris P. S., Baergen R. N., Wilcynski S. P., Costa M. J. et al. (1998) Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int. J. Cancer 77: 741-746
74. 74 Durant S. T., Morris M. M., Illand M., McKay H. J., McCormick C., Hirst G. L. et al. (1999) Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr. Biol. 9: 51-54
75. 75 Turchi J. J. and Henkels K. M. (1996) Human Ku autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase. J. Biol. Chem. 271: 13861-13867
76. 76 Comess K. M., Burstyn J. N., Essigmann J. M. and Lippard S. J. (1992) Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinm(II) DNA adducts. Biochemistry 31: 3975-3990
77. 77 Pillaire M. J., Hoffmann J. S., Defais M. and Villani G. (1995) Replication of DNA containing cisplatin lesions and its mutagenic consequences. Biochimie 77: 803-807
78. 78 Hoffmann J. S., Pillaire M. J., Lesca C., Burnouf D., Fuchs R. P., Defais M. et al. (1996) Fork-like DNA templates support bypass replication of lesions that block DNA synthesis on single-stranded templates. Proc. Natl. Acad. Sci. USA 93: 13766-13769
79. 79 Yarema K. J., Lippard S. J. and Essigmann J. M. (1995) Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II). Nucleic Acids Res. 23: 4066-4072
80. 80 Marra G. and Schär P. (1999) Recognition of DNA alterations by the mismatch repair system. Biochem. J. 388: 1-13
81. 81 Neijt J. P. (1997) Textbook of Medical Oncology, Cavalli F., Hansen H. H. and Kaye S. B. (eds), Martin Dunitz, London
82. 82 Raymond E., Faivre S., Woynarowski J. M. and Chaney S. G. (1998) Oxaliplatin: mechanism of action and antineoplastic activity. Sem. Oncol. 2(Suppl. 5): 4-12
83. 83 Ohndorf U.-M., Rould M. A., He Q., Pabo C. O. and Lippard S. J. (1999) Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature 399: 708-712
84. 84 Allain F. H.-T., Yen Y. M., Masse J. E., Schultze P., Dieckmann T., Johnson R. C. et al. (1999) Solution structure of the HMG-protein NHP6A and its interaction with DNA reveals the structural determinants for non-sequence-specific binding. EMBO J. 18: 2563-2579